Drug Profile
Research programme: pegfilgrastim biosimilar - Biogenomics
Alternative Names: PEG-GCSFLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Biogenomics
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Neutropenia(Chemotherapy-induced) in India (Parenteral, Injection)
- 16 Jan 2014 Research programme: pegfilgrastim biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
- 14 Jan 2014 Preclinical trials in Neutropenia in India (Parenteral)